World-renowned medical specialist joins TruScreen Board

World-renowned medical specialist joins TruScreen Board
19 October 2017
Cervical cancer technology company, TruScreen Limited (NZAX: TRU), is pleased to announce the
appointment of Professor Ron Jones as an independent director on the TruScreen Board, effective
from Tuesday, 17 October, 2017.
Prof. Jones is a retired obstetrician and gynaecologist and was a former clinical professor at the
University of Auckland, as well as serving on the Auckland University of Technology ethics
committee. He is a widely published international authority of lower genital tract pre-cancer and
cancer. For over 30 years he has served on a range of national and international committees
addressing the natural history, prevention and management of these cancers. He is a past president
of the International Society for the Study of Vulvovaginal Disease and chair of the Scientific
Committee of the International Federation of Cervical Pathology and Colposcopy.
Prof. Jones has been involved with the TruScreen technology since the very beginning and was the
Principal Investigator for a 1998 study at National Women’s Hospital in Auckland, one of the key
clinics used to gather early data for what was then the Cervical PolarProbe (and has now evolved
into TruScreen). The data generated in that study was used to “inform” or “train” the tissue
differentiating algorithm that was first placed into the TruScreen device.
Chairman of TruScreen, Mr Robert Hunter, commented: “We are privileged to have Prof. Jones join
the TruScreen Board. He is arguably one of New Zealand’s most highly qualified gynaecologists, has
been involved in a number of highly regarded international clinical studies on new clinical
technologies and has experience working with, and advising governments, at the highest level.
“TruScreen is now entering the commercialisation phase and presentations to health ministries and
key opinion leaders are a critical component of our business plan. Prof. Jones’ international profile
and his extensive experience and expertise will be a significant advantage for our company as we
look to expand and build on our global footprint.”
Prof. Jones is ordinarily resident in New Zealand and has been appointed by the current TruScreen
directors, as permitted under TruScreen’s constitution. He will hold office until TruScreen’s 2018
Annual Meeting at which time he will offer himself for election by shareholders. Following Prof.
Jones’ appointment the TruScreen Board will comprise of three independent directors and one non-
executive director.
ENDS
For more information visit www.truscreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@truscreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.